---
title: 'Overall survival with sacituzumab govitecan in hormone receptor-positive and
  human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02):
  a randomised, open-label, multicentre, phase 3 trial'
date: '2023-08-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37633306/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230827181309&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'BACKGROUND: Sacituzumab govitecan demonstrated significant progression-free
  survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with
  pretreated, endocrine-resistant hormone receptor-positive, human epidermal growth
  factor receptor 2-negative (HR+ and HER2-) metastatic breast cancer with limited
  treatment options. Here, we report the protocol-specified final analysis of overall
  survival and endpoints by trophoblast cell-surface antigen 2 (Trop-2) expression
  and ...'
disable_comments: true
---
BACKGROUND: Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2-) metastatic breast cancer with limited treatment options. Here, we report the protocol-specified final analysis of overall survival and endpoints by trophoblast cell-surface antigen 2 (Trop-2) expression and ...